Hilary Haack, DO
Family Medicine · Millsboro, DENPI 1861839623
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 264 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 15.2% — the pattern of someone who eats at a lot of different presentations.
Across 264 payments — averaging $17.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$700
- Pfizer$591
- AbbVie$492
- Amgen$481
- Lilly USA, LLC$449
- Merck$275
- plus $2K from 26 others
What the payments were for
- Food & beverage$4,606100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 45 | $700 |
| Pfizer | 27 | $591 |
| AbbVie(2 entities) | 31 | $492 |
| Amgen | 31 | $481 |
| Lilly USA, LLC | 27 | $449 |
| Merck | 14 | $275 |
| GSK | 14 | $262 |
| Boehringer Ingelheim | 10 | $154 |
| Abbott | 8 | $147 |
| Astellas Pharma US Inc | 6 | $131 |
| Exact Sciences | 6 | $129 |
| AstraZeneca | 7 | $116 |
| Bayer | 5 | $84 |
| E.r. Squibb & Sons, L.L.C. | 4 | $75 |
| Novartis | 3 | $58 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $52 |
| Kowa Pharmaceuticals America, Inc. | 3 | $48 |
| Phathom Pharmaceuticals, Inc. | 3 | $41 |
| Daiichi Sankyo Inc. | 2 | $40 |
| Otsuka America Pharmaceutical, Inc. | 2 | $37 |
| Aimmune Therapeutics, Inc. | 1 | $36 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $34 |
| Esperion Therapeutics, Inc. | 1 | $23 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $21 |
| Biomarin Pharmaceutical Inc. | 1 | $19 |
| Biogen | 1 | $19 |
| Lundbeck LLC | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
| Eisai Inc. | 1 | $12 |
| Shire North American Group Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PREVNAR - 13$129
How this compares
$4,606 in reported general payments places this provider in the 85th percentile of 352 family medicine providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 131 | $259,067 |
| RybelsusSemaglutide | 47 | $106,282 |
| EliquisApixaban | 60 | $96,258 |
| FarxigaDapagliflozin Propanediol | 66 | $93,625 |
| TrulicityDulaglutide | 38 | $68,452 |
| JardianceEmpagliflozin | 54 | $67,590 |
| MounjaroTirzepatide | 19 | $44,941 |
| XareltoRivaroxaban | 27 | $41,543 |
| InvokanaCanagliflozin | 20 | $25,262 |
| JanuviaSitagliptin Phosphate | 13 | $21,365 |
| Arnuity ElliptaFluticasone Furoate | 24 | $13,689 |
| Spiriva RespimatTiotropium Bromide | 22 | $13,015 |
| Atorvastatin Calcium | 850 | $11,778 |
| Rosuvastatin Calcium | 318 | $8,055 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $7,871 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $700 | $365,349178 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $449 | $113,39357 claims |
| PfizerEliquis | $591 | $96,25860 claims |
| AstraZenecaFarxiga | $116 | $93,62566 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $154 | $80,60576 claims |
| MerckJanuvia | $275 | $21,36513 claims |
| GSKArnuity Ellipta | $262 | $13,68924 claims |
| AbbVieSynthroid | $492 | $2,92386 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 352 family medicine providers in Delaware.
Other family medicine in Millsboro
- Danielle GiddinsMillsboro$5K
- James BeebeMillsboro$3K
- Carolyn OconorMillsboro$3K
- Gregory PapaNew Castle$67K
- Sarah MullinsWilmington$36K
- Ashley PanichelliWilmington$27K
- Michelle PapaNewark$23K
- Maryann ConnorWilmington$21K
- Jill MackeyWilmington$20K
- Wayne TuckerBear$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.